Importantly, CD40 agonists that depend on FcγRIIb crosslinking should have a more favorable safety profile because FcγRIIb-mediated crosslinking is most prevalent in tumor tissues and tumor-draining lymph nodes but limited in the circulation which could lead to less systemic APC activation and cytokine release. This evidence concerns the gene CD40 and neoplasm.